Any feedback?
Literature summary extracted from
- Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor (2004), J. Biol. Chem., 279, 6620-6628.
Cloned(Commentary)
| EC Number | Cloned (Comment) | Organism |
|---|---|---|
| 3.4.17.20 | expression of wild-type TAFI isozymes Thr147 and Thr325 and of two TAFI-carboxypeptidase B chimeric proteins, the CPB fragments fused to TAFI comprise residues 288-395 and 288-327, respectively, in baby hamster kidney cells | Homo sapiens |
| 3.4.17.20 | recombinant TAFI and TAFI/CPB(carboxypeptidase B) chimeras | Homo sapiens |
Protein Variants
| EC Number | Protein Variants | Comment | Organism |
|---|---|---|---|
| 3.4.17.20 | additional information | generation of a TAFI a form with a highly stable activity by replacing a region in TAFI with the corresponding region in pancreatic CPB (carboxypeptidase B). TAFI-CPB(293-333) can be activated by thrombin-thrombomodulin, but not as efficient as wild-type TAFI. After activation, this chimeric enzyme is unstable and hardly able to prolong clot lysis of TAFI-deficient plasma. Binding of the mutant enzyme to both plasminogen and fibrinogen is normal compared to wild-type TAFI. TAFI-CPB(293-401) can be activated by thrombin-thrombomodulin, although at a lower rate compared with wild-type TAFI. The activated mutant displays a markedly prolonged half-life of 1.5 h. The chimeric enzyme does not bind plasminogen and fibrinogen and can prolong the clot lysis time in TAFI-deficient plasma, although not as efficiently as wild-type TAFI | Homo sapiens |
| 3.4.17.20 | additional information | construction of chimeric proteins composed by wild-type TAFI isozymes Thr147 and Thr325, and carboxypeptidase B, CPB, fragments comprising residues 288-395 and 288-327, the chimeric mutants show increase stability and 32-34fold increased half-lives compared to the wild-type TAFI | Homo sapiens |
General Stability
| EC Number | General Stability | Organism |
|---|---|---|
| 3.4.17.20 | analysis of stability of recombinant wild-type and chimeric mutant isozymes, the chimeric mutants show increase stability and half-life compared to the wild-type TAFI, overview | Homo sapiens |
KM Value [mM]
| EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
|---|---|---|---|---|---|---|
| 3.4.17.20 | additional information | - |
additional information | binding kinetics of recombinant wild-type and chimeric mutant isozymes to fibrinogen and plasminogen, overview | Homo sapiens |
Natural Substrates/ Products (Substrates)
| EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 3.4.17.20 | additional information | Homo sapiens | the enzyme inhibits fibrinolysis | ? | - |
? |  |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.4.17.20 | Homo sapiens | - |
- |
- |
Posttranslational Modification
| EC Number | Posttranslational Modification | Comment | Organism |
|---|---|---|---|
| 3.4.17.20 | proteolytic modification | the recombinant pre-enzyme and pre-enzyme chimera are activated by thrombin/thrombomodulin in presence of Ca2+ through cleavage at Arg92 releasing the activation peptide, cleavage of Arg302 leads to inactivation by disruption of the active site, cleavage pattern with wild-type and chimeric muatnt enzymes, overview, plasmin activates inactive TAFI and inactivates active TAFI, overview | Homo sapiens |
Purification (Commentary)
| EC Number | Purification (Comment) | Organism |
|---|---|---|
| 3.4.17.20 | recombinant TAFI and TAFI/CPB(carboxypeptidase B) chimeras | Homo sapiens |
| 3.4.17.20 | recombinant wild-type TAFI isozymes Thr147 and Thr325 and TAFI-carboxypeptidase B chimeric proteins from baby hamster kidney cells by immunoaffinity and ion exchange chromatography | Homo sapiens |
Source Tissue
| EC Number | Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|---|
| 3.4.17.20 | plasma | - |
Homo sapiens | - |
Specific Activity [micromol/min/mg]
| EC Number | Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
|---|---|---|---|---|
| 3.4.17.20 | additional information | - |
binding capacity of recombinant wild-type and chimeric mutant isozymes to fibrinogen and plasminogen, overview | Homo sapiens |
Substrates and Products (Substrate)
| EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 3.4.17.20 | hippuryl-Arg + H2O | - |
Homo sapiens | hippuric acid + Arg | - |
? | |
| 3.4.17.20 | additional information | the enzyme inhibits fibrinolysis | Homo sapiens | ? | - |
? | |
Synonyms
| EC Number | Synonyms | Comment | Organism |
|---|---|---|---|
| 3.4.17.20 | activated thrombin-activable fibrinolysis inhibitor | - |
Homo sapiens |
| 3.4.17.20 | TAFIa | - |
Homo sapiens |
Temperature Optimum [°C]
| EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
|---|---|---|---|---|
| 3.4.17.20 | 37 | - |
assay at | Homo sapiens |
pH Optimum
| EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
|---|---|---|---|---|
| 3.4.17.20 | 7.4 | - |
assay at | Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
